Investment analysts at Wall Street Zen began coverage on shares of TherapeuticsMD (NASDAQ:TXMD – Get Free Report) in a report released on Wednesday. The brokerage set a “hold” rating on the stock.
TherapeuticsMD Stock Performance
Shares of NASDAQ:TXMD opened at $1.45 on Wednesday. The company’s 50 day moving average price is $1.13 and its two-hundred day moving average price is $1.13. TherapeuticsMD has a 12-month low of $0.70 and a 12-month high of $2.44.
TherapeuticsMD (NASDAQ:TXMD – Get Free Report) last announced its earnings results on Tuesday, May 13th. The company reported ($0.06) earnings per share (EPS) for the quarter. TherapeuticsMD had a negative return on equity of 14.08% and a negative net margin of 207.77%. The business had revenue of $0.39 million for the quarter.
About TherapeuticsMD
TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.
See Also
- Five stocks we like better than TherapeuticsMD
- What is the Shanghai Stock Exchange Composite Index?
- Turbulence for Joby Shares: What’s Behind the Recent Dip?
- Using the MarketBeat Dividend Yield Calculator
- Why Carnival Could Be the Ultimate Non-Tech Growth Stock
- How to Profit From Value Investing
- Super Micro Computer Stock Clears New Path Higher on Saudi Orders
Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.
